Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B
KING OF PRUSSIA, PA — Global biotherapeutics leader CSL Behring announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare Part B for the treatment …
Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Read More